My patients think going onto APO-go is one of the last options available to them and indicates the end stage of their disease. How do I reassure them?
Parkinson’s disease is a degenerative disease and over time a narrowing therapeutic window is a limiting factor for optimal dose titration with oral therapies. CDS is known to reverse this and so reduce motor complications and improve quality of life for patients as long as the therapeutic window hasn’t been allowed to narrow too far. APO-go CDS offers patients improved disease management when their oral education is failing. APO-go is a highly potent and valuable part of the non-invasive therapeutic armamentarium and should be considered before more invasive interventions. Patients can be on APO-go therapy for many years, and then as the disease progresses additional treatment options are available.
